- Trials with a EudraCT protocol (44)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44 result(s) found for: Beta chain.
Displaying page 1 of 3.
EudraCT Number: 2012-002499-15 | Sponsor Protocol Number: A536-04 | Start Date*: 2012-12-19 | ||||||||||||||||
Sponsor Name:ACCELERON PHARMA INC | ||||||||||||||||||
Full Title: A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients with β-Thalassemia Intermedia | ||||||||||||||||||
Medical condition: β-thalassemia intermedia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) GR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000695-42 | Sponsor Protocol Number: HGB-205 | Start Date*: 2012-12-31 | |||||||||||
Sponsor Name:bluebird bio, Inc. | |||||||||||||
Full Title: A Phase I/II Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the β-Hemoglobinopathies (Sickle Cell Anemia and β-Thalassemia Major) by Transplantation of Autologous CD34+ Stem... | |||||||||||||
Medical condition: Severe sickle cell anemia and transfusion-dependent beta-thalassemia major. This study will enroll patients who are eligible for an allogeneic hematopoietic stem cell transplant (HSCT) but do not... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001567-55 | Sponsor Protocol Number: DAC-1012 | Start Date*: 2006-06-23 |
Sponsor Name:Protein Design Labs, Inc. | ||
Full Title: A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis | ||
Medical condition: This study is performed in patients with relapsing forms of Multiple Sclerosis. Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS), thought ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) GB (Completed) ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001539-10 | Sponsor Protocol Number: UX007-CL302 | Start Date*: 2022-12-27 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared with Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patient... | |||||||||||||
Medical condition: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000040-13 | Sponsor Protocol Number: 21011075118 | Start Date*: 2009-02-11 |
Sponsor Name:Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie | ||
Full Title: Effects of recombinant human Erythropoietin on circulating and intramuscular endothelial progenitor cells, neovascularisation and oxidative metabolism of skeletal muscle in Friedreich’s Ataxia | ||
Medical condition: Friedreich's ataxia (FRDA) is the most common autosomal recessive neurodegenerativ disease (1:50 000) affecting the central and peripheral nervous system. Extraneural organs are also affected durin... | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-006686-32 | Sponsor Protocol Number: EC07/90573 | Start Date*: 2008-05-22 |
Sponsor Name:FUNDACIÓN INVESTIGACIÓN BIOMEDICA DEL HOSPITAL CLINICO SAN CARLOS | ||
Full Title: Identificación de biomarcadores proteicos asociados a resistencia a la aspirina y a tienopiridinas en pacientes con cardiopatía isquémica establecida. (ESTUDIO BIRAT). Identification of new protei... | ||
Medical condition: To determine proteins in plasma, leukocytes and platelets associated with aspirin resistance syndrome in stable coronary artery disease patients that may allow us to identify them.It is probably th... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001242-35 | Sponsor Protocol Number: 68284528MMY3004 | Start Date*: 2021-08-02 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA... | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) NL (Ongoing) CZ (Trial now transitioned) ES (Ongoing) HU (Ongoing) AT (Trial now transitioned) IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000181-39 | Sponsor Protocol Number: C0168X84, EU-0108 | Start Date*: 2005-08-31 |
Sponsor Name:Med. Universitaetsklinik Graz, ao Univ. Professor Dr. med. Thomas C. Wascher | ||
Full Title: A Prospective Trial of Anti-TNF-a Chimeric Monoclonal Antibody (infliximab, Remicade®) on Insulin Sensitivity, Beta Cell Function and Cardiovascular Risk Profile in Insulin Resistant Human Obesity | ||
Medical condition: Insulin Resistant Human Obesity | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000455-39 | Sponsor Protocol Number: C21-109-09 | Start Date*: 2021-04-09 | |||||||||||
Sponsor Name:Pharma Holdings AS | |||||||||||||
Full Title: A double-blind, placebo-controlled, interventional parallel group study to evaluate the antiviral effect of a single nasal application of LTX-109 3% gel, in comparison to placebo gel, in subjects w... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001684-21 | Sponsor Protocol Number: NV1205-009 | Start Date*: 2018-04-20 |
Sponsor Name:Neurov Acquisition LLC | ||
Full Title: Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD) | ||
Medical condition: Childhood Cerebral Adrenoleukodystrophy (CCALD) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |
Trial protocol: GB (Prematurely Ended) FR (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2017-004388-11 | Sponsor Protocol Number: EIP-VX17-745-304 | Start Date*: 2018-10-11 | |||||||||||
Sponsor Name:EIP Pharma Inc | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects with Mild Alzheimer’s Disease | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DK (Completed) NL (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000167-69 | Sponsor Protocol Number: AIC649-02-II-01 | Start Date*: 2021-06-30 | |||||||||||
Sponsor Name:AiCuris Anti-Infective Cures AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AIC649 in the treatment of otherwise healthy subjects with asymptomatic or mildly symptomatic SARS-CoV-2 ... | |||||||||||||
Medical condition: asymptomatic or mildly symptomatic SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001109-22 | Sponsor Protocol Number: PBGM01-001 | Start Date*: Information not available in EudraCT |
Sponsor Name:Passage Bio, Inc. | ||
Full Title: A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Su... | ||
Medical condition: GM1 gangliosidosis (GM1) is an autosomal recessive disorder that results from mutations in the human galactosidase beta 1 gene (GLB1), which encodes beta-galactosidase (β-gal). | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001052-39 | Sponsor Protocol Number: ARRAY-520-311 | Start Date*: 2014-11-02 | |||||||||||
Sponsor Name:Array BioPharma Inc. | |||||||||||||
Full Title: The FACTOR Study (Filanesib and Carfilzomib Treatment of Relapsed/Refractory Multiple Myeloma): A Multinational, Randomized, Open-label Phase 3 Study of Filanesib (ARRY-520) + Carfilzomib Versus ... | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) AT (Completed) DE (Completed) CZ (Completed) GB (Completed) HU (Completed) ES (Completed) BE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003781-40 | Sponsor Protocol Number: GCT3014-01 | Start Date*: 2021-01-11 | ||||||||||||||||
Sponsor Name:Genmab A/S | ||||||||||||||||||
Full Title: An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies | ||||||||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) FR (Ongoing) NL (Ongoing) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004726-34 | Sponsor Protocol Number: SHP620-302 | Start Date*: 2017-09-01 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegaloviru... | |||||||||||||
Medical condition: Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) CZ (Completed) PL (Completed) FR (Completed) HR (Completed) IT (Completed) GR (Completed) AT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002457-69 | Sponsor Protocol Number: CP-MGA031-01 | Start Date*: 2008-12-04 | |||||||||||
Sponsor Name:MacroGenics, Inc. | |||||||||||||
Full Title: A Phase 2/3, Randomized, Double-Blind, Multicenter, Multinational, 4-Arm, Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-C... | |||||||||||||
Medical condition: Recent-onset type I diabetes mellitus (T1DM) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) SE (Completed) GB (Completed) EE (Completed) NL (Completed) LV (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000653-39 | Sponsor Protocol Number: IMR-SCD-102 | Start Date*: 2017-10-19 | |||||||||||
Sponsor Name:Imara, Inc | |||||||||||||
Full Title: A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia) | |||||||||||||
Medical condition: Sickle cell disease (SCD) is a rare inherited red blood cell (RBC) disorder characterized by chronic hemolysis, debilitating pain, progressive multiorgan damage, and premature death. SCD is caused ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001182-41 | Sponsor Protocol Number: C0168X97 | Start Date*: 2007-03-27 | |||||||||||
Sponsor Name:Ass.Prof. Petros Sfikakis | |||||||||||||
Full Title: Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: a Randomized, Double-Masked, Placebo-Controlled, Cross-over, 32 Weeks Study | |||||||||||||
Medical condition: Diabetic Macular Oedema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000244-26 | Sponsor Protocol Number: PC-ASP-004 | Start Date*: 2018-08-21 | ||||||||||||||||
Sponsor Name:Pulmocide Ltd | ||||||||||||||||||
Full Title: A double-blind, placebo-controlled study to assess the effects of inhaled PC945 in the treatment of culture-positive Aspergillus or Candida fungal bronchitis in subjects with moderate to severe ast... | ||||||||||||||||||
Medical condition: Pulmonary aspergillosis and candidiasis of lung | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
